These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 28953345)

  • 21. Paying for Prescription Drugs Around the World: Why Is the U.S. an Outlier?
    Sarnak DO; Squires D; Kuzmak G; Bishop S
    Issue Brief (Commonw Fund); 2017 Oct; 2017():1-14. PubMed ID: 28990747
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug expenditure in Ireland 1997-2007.
    Barry M; Molloy D; Usher C; Tilson L
    Ir Med J; 2008; 101(10):299-302. PubMed ID: 19205138
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmaceuticals: pharmaceutical cost controls--2005. End of Year Issue Brief.
    Seay M; Varma P
    Issue Brief Health Policy Track Serv; 2005 Dec; ():1-20. PubMed ID: 16708455
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Higher US branded drug prices and spending compared to other countries may stem partly from quick uptake of new drugs.
    Kanavos P; Ferrario A; Vandoros S; Anderson GF
    Health Aff (Millwood); 2013 Apr; 32(4):753-61. PubMed ID: 23569056
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differences in the cost of antidepressants across state Medicaid programs.
    Kelton CM; Rebelein RP; Heaton PC; Ferrand Y; Guo JJ
    J Ment Health Policy Econ; 2008 Mar; 11(1):33-47. PubMed ID: 18424875
    [TBL] [Abstract][Full Text] [Related]  

  • 26. International best practices for negotiating 'reimbursement contracts' with price rebates from pharmaceutical companies.
    Morgan S; Daw J; Thomson P
    Health Aff (Millwood); 2013 Apr; 32(4):771-7. PubMed ID: 23569058
    [TBL] [Abstract][Full Text] [Related]  

  • 27. State strategies to address medicaid prescription spending: negotiated pricing vs price transparency.
    Noh S; Janousek CL; Park JH
    Health Econ Policy Law; 2021 Apr; 16(2):201-215. PubMed ID: 32349843
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pursuing Value-Based Prices for Drugs: A Comprehensive Comparison of State Prescription Drug-Pricing Boards.
    Bendicksen L; Rome BN; Avorn J; Kesselheim AS
    Milbank Q; 2021 Dec; 99(4):1162-1197. PubMed ID: 34375015
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Examining Misaligned Incentives for Payers and Manufacturers in Value-Based Pharmaceutical Contracts.
    Kannarkat JT; Good CB; Kelly E; Parekh N
    J Manag Care Spec Pharm; 2020 Jan; 26(1):63-66. PubMed ID: 31880231
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of final short-fill rule on Medicare Part D costs and long-term care pharmacy dispensing.
    Bazalo G; Weiss RC
    Consult Pharm; 2012 Apr; 27(4):269-73. PubMed ID: 22498986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A New Focus on Prescription Drug Spending.
    Wilensky G
    JAMA; 2015 Aug; 314(5):440-1. PubMed ID: 26241584
    [No Abstract]   [Full Text] [Related]  

  • 32. National Health Spending In 2014: Faster Growth Driven By Coverage Expansion And Prescription Drug Spending.
    Martin AB; Hartman M; Benson J; Catlin A;
    Health Aff (Millwood); 2016 Jan; 35(1):150-60. PubMed ID: 26631494
    [TBL] [Abstract][Full Text] [Related]  

  • 33. It took two decades for private payor contracts to erode the bottom line: plan on a 2+ year comeback--here's how, Part IV.
    Noyes P
    J Med Pract Manage; 2008; 24(2):105-10. PubMed ID: 19174971
    [TBL] [Abstract][Full Text] [Related]  

  • 34. National health expenditure projections, 2014-24: spending growth faster than recent trends.
    Keehan SP; Cuckler GA; Sisko AM; Madison AJ; Smith SD; Stone DA; Poisal JA; Wolfe CJ; Lizonitz JM
    Health Aff (Millwood); 2015 Aug; 34(8):1407-17. PubMed ID: 26220668
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Good research practices for measuring drug costs in cost-effectiveness analyses: Medicare, Medicaid and other US government payers perspectives: the ISPOR Drug Cost Task Force report--Part IV.
    Mullins CD; Seal B; Seoane-Vazquez E; Sankaranarayanan J; Asche CV; Jayadevappa R; Lee WC; Romanus DK; Wang J; Hay JW; Smeeding J
    Value Health; 2010; 13(1):18-24. PubMed ID: 19807903
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of pharmacy services in accountable care organizations.
    Colla CH; Lewis VA; Beaulieu-Jones BR; Morden NE
    J Manag Care Spec Pharm; 2015 Apr; 21(4):338-44. PubMed ID: 25803767
    [TBL] [Abstract][Full Text] [Related]  

  • 37. How to Hit a Home Run with Bundled Payments.
    Kaldy J
    Consult Pharm; 2015 Sep; 30(9):492-504. PubMed ID: 26350890
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changing prescription drug sector: new expenditure methodologies.
    Genuardi JS; Stiller JM; Trapnell GR
    Health Care Financ Rev; 1996; 17(3):191-204. PubMed ID: 10158730
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Understanding Payer Perspectives on Value in the Use of Pharmaceuticals in the United States.
    Brogan AP; Hogue SL; Vekaria RM; Reynolds I; Coukell A
    J Manag Care Spec Pharm; 2019 Dec; 25(12):1319-1327. PubMed ID: 31778613
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Frequency of hospitalizations prior to and after conversion to a rebate pharmaceutical in depression patients in Germany.
    Kostev K; May U; Ott C; Paul M; Schetschok K; Tingelhoff M; Claus C; Waehlert L
    Int J Clin Pharmacol Ther; 2013 May; 51(5):416-22. PubMed ID: 23547855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.